175 related articles for article (PubMed ID: 36967442)
21. Synergistic inhibition of metastatic breast cancer by dual-chemotherapy with excipient-free rhein/DOX nanodispersions.
Wang R; Yang Y; Yang M; Yuan D; Huang J; Chen R; Wang H; Hu L; Di L; Li J
J Nanobiotechnology; 2020 Aug; 18(1):116. PubMed ID: 32847586
[TBL] [Abstract][Full Text] [Related]
22. Resveratrol reverses Doxorubicin resistance by inhibiting epithelial-mesenchymal transition (EMT) through modulating PTEN/Akt signaling pathway in gastric cancer.
Xu J; Liu D; Niu H; Zhu G; Xu Y; Ye D; Li J; Zhang Q
J Exp Clin Cancer Res; 2017 Jan; 36(1):19. PubMed ID: 28126034
[TBL] [Abstract][Full Text] [Related]
23. Enhancing therapeutic efficacy in breast cancer: a study on the combined cytotoxic effects of doxorubicin and MPC-3100.
Gökşen Tosun N
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3249-3259. PubMed ID: 37917369
[TBL] [Abstract][Full Text] [Related]
24. Lupeol synergizes with doxorubicin to induce anti-proliferative and apoptotic effects on breast cancer cells.
Malekinejad F; Kheradmand F; Khadem-Ansari MH; Malekinejad H
Daru; 2022 Jun; 30(1):103-115. PubMed ID: 35113358
[TBL] [Abstract][Full Text] [Related]
25. Camel Urine Promotes Sensitization to Doxorubicin by Inhibiting Epithelial-Mesenchymal Transition and Modulating NF-κB-Snail Signaling Pathway in Breast Cancer Cells.
Al-Mutairi MS; Matar IK; Alfadli S; Al-Mutairi A
Asian Pac J Cancer Prev; 2021 Dec; 22(12):4017-4029. PubMed ID: 34967584
[TBL] [Abstract][Full Text] [Related]
26. Decitabine potentiates efficacy of doxorubicin in a preclinical trastuzumab-resistant HER2-positive breast cancer models.
Buocikova V; Longhin EM; Pilalis E; Mastrokalou C; Miklikova S; Cihova M; Poturnayova A; Mackova K; Babelova A; Trnkova L; El Yamani N; Zheng C; Rios-Mondragon I; Labudova M; Csaderova L; Kuracinova KM; Makovicky P; Kucerova L; Matuskova M; Cimpan MR; Dusinska M; Babal P; Chatziioannou A; Gabelova A; Rundén-Pran E; Smolkova B
Biomed Pharmacother; 2022 Mar; 147():112662. PubMed ID: 35091237
[TBL] [Abstract][Full Text] [Related]
27. Identification of 2,4-dihydroxy-5-pyrimidinyl imidothiocarbomate as a novel inhibitor to Y box binding protein-1 (YB-1) and its therapeutic actions against breast cancer.
Gunasekaran VP; Nishi K; Sivakumar D; Sivaraman T; Mathan G
Eur J Pharm Sci; 2018 Apr; 116():2-14. PubMed ID: 28916481
[TBL] [Abstract][Full Text] [Related]
28. A pH-sensitive nanotherapeutic system based on a marine sulfated polysaccharide for the treatment of metastatic breast cancer through combining chemotherapy and COX-2 inhibition.
Zhang T; Liu H; Li Y; Li C; Wan G; Chen B; Li C; Wang Y
Acta Biomater; 2019 Nov; 99():412-425. PubMed ID: 31494294
[TBL] [Abstract][Full Text] [Related]
29. Resveratrol promotes sensitization to Doxorubicin by inhibiting epithelial-mesenchymal transition and modulating SIRT1/β-catenin signaling pathway in breast cancer.
Jin X; Wei Y; Liu Y; Lu X; Ding F; Wang J; Yang S
Cancer Med; 2019 Mar; 8(3):1246-1257. PubMed ID: 30697969
[TBL] [Abstract][Full Text] [Related]
30. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
31. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
[TBL] [Abstract][Full Text] [Related]
32. Nitric oxide-releasing nanoparticles improve doxorubicin anticancer activity.
Alimoradi H; Greish K; Barzegar-Fallah A; Alshaibani L; Pittalà V
Int J Nanomedicine; 2018; 13():7771-7787. PubMed ID: 30538458
[TBL] [Abstract][Full Text] [Related]
33. CCA-1.1, a Novel Curcumin Analog, Exerts Cytotoxic anti- Migratory Activity toward TNBC and HER2-Enriched Breast Cancer Cells.
Novitasari D; Jenie RI; Utomo RY; Kato JY; Meiyanto E
Asian Pac J Cancer Prev; 2021 Jun; 22(6):1827-1836. PubMed ID: 34181339
[TBL] [Abstract][Full Text] [Related]
34. Strobilanthes crispus inhibits migration, invasion and metastasis in breast cancer.
Baraya YS; Wong KK; Yaacob NS
J Ethnopharmacol; 2019 Apr; 233():13-21. PubMed ID: 30594607
[TBL] [Abstract][Full Text] [Related]
35. α- Tocopherol succinate loaded nano-structed lipid carriers improves antitumor activity of doxorubicin in breast cancer models in vivo.
Fernandes RS; Silva JO; Seabra HA; Oliveira MS; Carregal VM; Vilela JMC; Andrade MS; Townsend DM; Colletti PM; Leite EA; Cardoso VN; Ferreira LAM; Rubello D; Barros ALB
Biomed Pharmacother; 2018 Jul; 103():1348-1354. PubMed ID: 29864917
[TBL] [Abstract][Full Text] [Related]
36. The Synergistic Anticancer Traits of Graphene Oxide Plus Doxorubicin Against BT474 and MCF7 Breast Cancer Stem Cells In Vitro.
Ebrahimi M; Teimouri M; Pooladi M
Appl Biochem Biotechnol; 2021 Nov; 193(11):3586-3601. PubMed ID: 34324153
[TBL] [Abstract][Full Text] [Related]
37. Suppression of Tumor Growth and Cell Migration by Indole-Based Benzenesulfonamides and Their Synergistic Effects in Combination with Doxorubicin.
Nguyen PL; Elkamhawy A; Choi YH; Lee CH; Lee K; Cho J
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077298
[TBL] [Abstract][Full Text] [Related]
38. Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells.
Hashemi-Niasari F; Rabbani-Chadegani A; Razmi M; Fallah S
Biomed Pharmacother; 2018 Oct; 106():858-867. PubMed ID: 30119256
[TBL] [Abstract][Full Text] [Related]
39. The effects of β-caryophyllene oxide and trans-nerolidol on the efficacy of doxorubicin in breast cancer cells and breast tumor-bearing mice.
Hanušová V; Caltová K; Svobodová H; Ambrož M; Skarka A; Murínová N; Králová V; Tomšík P; Skálová L
Biomed Pharmacother; 2017 Nov; 95():828-836. PubMed ID: 28903178
[TBL] [Abstract][Full Text] [Related]
40. Ozone combined with doxorubicin exerts cytotoxic and anticancer effects on Luminal-A subtype human breast cancer cell line.
Karagulle OO; Yurttas AG
Rev Assoc Med Bras (1992); 2022 Apr; 68(4):507-513. PubMed ID: 35649075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
